102
H.R. Memarian et al. / Journal of Photochemistry and Photobiology A: Chemistry 209 (2010) 95–103
4.17. 5-Acetyl-4-(2ꢀ-methoxyphenyl)-6-methylpyrimidin-2(1H)-
one (2e)
132.24, 137.40, 156.52, 161.20, 168.92, 201.01. EI-MS: m/z (%):
308 (M+81Br, 38), 307 (M+81Br–H, 32), 306 (M+79Br, 37), 305
(M+79Br–H, 26), 293 (M+81Br–CH3, 81), 291 (M+79Br–CH3, 83), 265
(M+81Br–CH3CO, 6), 263 (M+79Br–CH3CO, 7), 227 (M+−Br, 24), 185
(4-81BrC6H4CH NH+, 16), 183 (4-79BrC6H4CH NH+, 61), 182 (4-
79BrC6H4C NH+, 16), 181 (4-79BrC6H4CN+, 45).
Pale yellow solid. Mp: 166–167 ◦C. IR: ꢁ 1960, 1590, 1550 cm−1
.
UV (CH3CN): ꢀmax (log ε) 303 nm (4.15), 258 (4.15). 1H NMR
(300 MHz, DMSO-d6): ı 1.87 (s, 3H, CH3), 2.32 (s, 3H, CH3CO),
3.70 (s, 3H, CH3O), 7.24 (mc, 4H, H-aromatic), 12.12 (brd s, 1H,
NH). 13C NMR (75.48 MHz, DMSO-d6): ı = 30.85, 55.58, 111.78,
119.24, 121.18, 130.54, 132.44, 155.96, 198.82. EI-MS: m/z (%):
258 (M+, 6), 257 (M+−H, 4), 243 (M+−CH3, 13), 227 (M+−CH3O,
100), 215 (M+−CH3CO, 22), 134 (2-CH3OC6H4–CH NH+, 38), 133
(2-CH3OC6H4–C NH+, 10), 132 (2-CH3OC6H4–CN+, 6).
4.22. 5-Acetyl-4-(2ꢀ-bromophenyl)-6-methylpyrimidin-2(1H)-
one (2j)
Pale yellow solid. Mp: 202–204 ◦C. IR: ꢁ 1700, 1615, 1420 cm−1
.
UV (CH3CN): ꢀmax (log ε) 301.5 nm (3.89), 264 (3.86). 1H NMR
(300 MHz, DMSO-d6): ı 1.85 (s, 3H, CH3), 2.37 (s, 3H, CH3CO), 7.43
(mc, 3H, H-aromatic), 7.73 (d, J = 7.82 Hz, 1H, 6-Hꢀ), 12.36 (brd s, 1H,
NH). EI-MS: m/z (%): 227 (M+−Br, 100), 185 (2-81BrC6H4CH NH+,
10), 184 (2-81BrC6H4C NH+, 26) 183 (4-79BrC6H4CH NH+, 3), 182
(4-79BrC6H4C NH+, 6).
4.18. 5-Acetyl-4-(4ꢀ-chlorophenyl)-6-methylpyrimidin-2(1H)-
one (2f)
Pale yellow solid. Mp: 235–237 ◦C. IR:
ꢁ 1650, 1580,
1420 cm−1. UV (CH3CN): ꢀmax (log ε) 313 nm (3.35), 252 (3.56).
1H NMR (300 MHz, DMSO-d6): ı 1.90 (s, 3H, CH3), 2.30 (s,
3H, CH3CO), 7.49 (d, J 8.27 Hz, 2H, 3-Hꢀ and 5-Hꢀ), 7.58 (d,
J = 8.21 Hz, 2H, 2-Hꢀ and 6-Hꢀ), 12.21 (brd s, 1H, NH).). 13C NMR
(75.48 MHz, DMSO-d6): ı = 18.97, 32.53, 118.30, 129.33, 130.51,
136.09, 137.02, 156.35, 161.11, 168.92, 200.99. EI-MS: m/z (%):
264 (M+37Cl, 27), 263 (M+37Cl–H, 32), 262 (M+35Cl, 78), 261
(M+35Cl–H, 59), 249 (M+37Cl–CH3, 69), 247 (M+35Cl–CH3, 99), 227
(M+−Cl, 17), 221 (M+37Cl–CH3CO, 5), 219 (M+35Cl–CH3CO, 13),
140 (4-37ClC6H4C NH+, 42), 139 (4-37ClC6H4CN+, 19), 138 (4-
35ClC6H4C NH+, 87), 137 (4-35ClC6H4CN+, 12).
4.23. 5-Acetyl-6-methyl-4-(4’-nitrophenyl)pyrimidine-2(1H)-
one (2k)
Pale yellow solid. Mp: 265–267 ◦C. IR: ꢁ 1665, 1600, 1505 cm−1
.
UV (CH3CN): ꢀmax (log ε) 330 nm (sh, 3.71), 302 (sh, 3.86), 262.0
(4.07). 1H NMR (300 MHz, DMSO-d6): ı 1.95 (s, 3H, CH3), 2.35 (s, 3H,
CH3CO), 7.73 (d, J = 8.52 Hz, 2H, 2-Hꢀ and 6-Hꢀ), 8.33 (d, J = 8.49 Hz,
2H, 3-Hꢀ and 5-Hꢀ), 9.27 (s, 1H, NH), 12.48 (brd s, 1H, NH). 13C NMR
(75.48 MHz, DMSO-d6): ı = 18.83, 124.33, 130.06, 144.44, 148.98.
EI-MS: m/z (%): 273 (M+, 20), 272 (M+−H, 13), 258 (M+−CH3, 100),
256 (M+−OH, 25), 226 (M+−HNO2, 12).
4.19. 5-Acetyl-4-(3ꢀ-chlorophenyl)-6-methylpyrimidin-2(1H)-
one (2g)
4.24. 5-Acetyl-6-methyl-4-(3’-nitrophenyl)pyrimidine-2(1H)-
one (2l)
Pale yellow solid. Mp: 196–198 ◦C. IR: ꢁ 1650, 1580, 1430 cm−1
.
Pale yellow solid. Mp: 256-258 ◦C. IR: ꢁ 1675, 159, 1520 cm−1
.
UV (CH3CN): ꢀmax (log ε) 320 nm (sh, 3.99), 304 (4.03), 259 (4.18).
1H NMR (300 MHz, DMSO-d6): ı 1.90 (s, 3H, CH3), 2.30 (s, 3H,
CH3CO), 7.54 (mc, 4H, H-aromatic), 9.27 (s, 1H, NH). 13C-NMR
(75.48 MHz, DMSO-d6): ı = 19.13, 32.55, 118.37, 127.31, 128.32,
130.89, 131.09, 133.93, 140.37, 156.73, 161.39, 168.58, 200.95. EI-
MS: m/z (%): 264 (M+37Cl, 21), 263 (M+37Cl–H, 23), 262 (M+35Cl,
58), 261 (M+35Cl–H, 38), 249 (M+37Cl–CH3, 45), 247 (M+35Cl–CH3,
100), 227 (M+−Cl, 14), 221 (M+37Cl–CH3CO, 5), 219 (M+35Cl–CH3CO,
9), 140 (3-37ClC6H4C NH+, 36), 139 (3-37ClC6H4CN+, 18), 138 (3-
35ClC6H4C NH+, 78), 137 (3-35ClC6H4CN+, 9).
UV (CH3CN): ꢀmax (log ε) 305.0 nm (3.57), 259.0 (3.85). 1H NMR
(300 MHz, DMSO-d6): ı 1.97 (s, 3H, CH3), 2.35 (s, 3H, CH3CO), 7.80
(t, J = 8.80 Hz, 1H, 5-Hꢀ), 7.88 (d, J = 7.49 Hz, 1H, 6-Hꢀ), 8.29 (s, 1H,
2-Hꢀ), 8.39 (d, J = 7.96 Hz, 1H, 4-Hꢀ), 12.48 (brd s, 1H, NH). 13C-NMR
(75.48 MHz, DMSO-d6): ı = 32.68, 123.37, 125.69, 130.96, 134.92,
148.28. EI-MS: m/z (%): 273 (M+, 15), 272 (M+−H, 8), 258 (M+−CH3,
100), 256 (M+−OH, 30), 226 (M+−HNO2, 16).
Acknowledgements
4.20. 5-Acetyl-4-(2ꢀ-chlorophenyl)-6-methylpyrimidin-2(1H)-
one (2h)
We are thankful to the Center of Excellence (Chemistry),
Research Council and Office of Graduate Studies of the University
of Isfahan for their financial support.
Pale yellow solid. Mp: 175–176 ◦C. IR: ꢁ 1700, 1620, 1430 cm−1
.
UV (CH3CN): ꢀmax (log ε) 305 nm (3.34), 259 (3.45). 1H NMR
(300 MHz, DMSO-d6): ı 1.90 (s, 3H, CH3), 2.30 (s, 3H, CH3CO),
7.47 (mc, 4H, H-aromatic), 12.26 (brd s, 1H, NH). 13C NMR
(75.48 MHz, DMSO-d6): ı = 20.23, 31.50, 119.22, 127.88, 130.06,
130.54, 131.00, 131.61, 137.32, 156.67, 163.00, 198.89. EI-MS: m/z
(%): 247 (M+35Cl–CH3, 5), 227 (M+−Cl, 100), 219 (M+35Cl–CH3CO,
3), 140 (2-37ClC6H4C NH+, 24), 139 (2-37ClC6H4CN+, 13) 138 (2-
35ClC6H4C NH+, 47), 137 (2-35ClC6H4CN+, 8).
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
References
[1] G.C. Rovnyak, S.D. Kimball, B. Beyer, G. Cucinotta, D.J. Dimarco, J. Gougoutas, A.
Hed, M. Malley, P.J. Mccarthy, R. Zhang, S. Moreland, Calcium entry blockers and
activators: conformational and structural determinants of dihydropyrimidine
calcium channel modulators, J. Med. Chem. 38 (1995) 119–129.
[2] W. Zhou, G. Gumina, Y. Chong, J. Wang, R.F. Schinazi, C.K. Chu, Synthesis,
structure–activity relationships, and drug resistance of -d-3ꢀ-fluoro-2ꢀ,3ꢀ-
unsaturated nucleosides as anti-HIV agents, J. Med. Chem. 47 (2004)
3399–3408.
4.21. 5-Acetyl-4-(4ꢀ-bromophenyl)-6-methylpyrimidin-2(1H)-
one (2i)
Pale yellow solid. Mp: 239–240 ◦C. IR: ꢁ 1670, 1620, 1420 cm−1
.
UV (CH3CN): ꢀmax (log ε) 322 nm (sh, 2.36), 304 (sh, 3.48), 252
(3.76). 1H NMR (300 MHz, DMSO-d6): ı 1.91 (s, 3H, CH3), 2.30
(s, 3H, CH3CO), 7.41 (d, J = 8.18 Hz, 2H, 3-Hꢀ and 5-Hꢀ), 7.72 (d,
J = 8.12 Hz, 2H, 2-Hꢀ and 6-Hꢀ), 12.30 (brd s, 1H, NH). 13C NMR
(75.48 MHz, DMSO-d6): ı = 19.02, 32.56, 118.30, 124.88, 130.70,
ˇ
[3] J.M. Blacquiere, O. Sicora, C.M. Vogels, M. Cuperlovic´-Culf, A. Decken, R.J. Ouel-
lelte, S.A. Westcott, Dihydropyrimidinones containing boronic acids, Can. J.
Chem. 83 (2005) 2052–2059.
[4] M. Brands, R. Endermann, R. Gahlmann, J. Krüger, S. Raddatz,
Dihydropyrimidinones—a new class of anti-Staphylococcal antibiotics,
Bioorg. Med. Chem. Lett. 13 (2003) 241–245.